On The Impact Of Prescription Point A On Hr-Ctv In Mri-Guided Hdr Brachytherapy For Cervical Cancer

Y. Huang,Y. Kim

DOI: https://doi.org/10.1016/j.ijrobp.2010.07.998

2010-01-01

Abstract:Point A remains the most frequent prescription (Rx) method (76%) in United States since high risk (HR)-CTV is unclear on CT. HR-CTV based Rx is 14%. Recent advent of high resolution (3.0 Tesla) MRI in gynecological cancer brachytherapy (BT) allows clinicians to deliver radiation dose in an adaptive way based on macroscopic tumor volume and tumor regression. The D90 (minimum dose delivered to 90% of the volume) of HR-CTV is recommended as Rx in MRI-guided BT plans. Hence, we investigate the consequences of prescribing dose to Point A on HR-CTV coverage for different Point A definitions. The Point A doses are also evaluated in MRI-guided plans that are optimized for the D90 of HR-CTV to receive Rx. We retrospectively studied 25 HDR plans of six patients with FIGO state Ib1-IV cervical cancer. Three different Point A definitions were explored: a revised Manchester Point A (POINT A), the Point A utilized at the University of Iowa (POINT A-UI: superiorly move from the tip of ovoids), and the POINT H as recently proposed by the ABS. Each plan was renormalized for each POINT to receive Rx. The IR (intermediate)-CTV, HR-CTV, rectum, bladder, and sigmoid were delineated on MRI. A MRI-guided plan for each plan was retrospectively generated. A tandem and ovoids applicator set was utilized for all plans. The HR-CTV coverage in conventional plans was significantly affected by the volume of HR-CTV but minimally by the POINT A definitions. When normalized to Rx, the percent (absolute) dose differences in HR-CTV (D90) were on average -10.1 ± 27.7% (-0.7Gy), -11.0 ± 28.0% (-0.7Gy), and -10.3 ± 28.2% (-0.7Gy) for POINT H, A, and A-UI, respectively. For all sizes of HR-CTV, the doses of different POINT were higher than HR-CTV (D90). For small volume of HR-CTV (<20cc), the differences were +13.5 ± 22.0% (0.7Gy), +12.5 ± 23.1% (0.6Gy), and +14.8 ± 20.8% (0.8Gy). For small volume, the D90 of HR-CTV was higher than POINT doses. For large volume (≥40cc), -35.6 ± 17.6% (-2.2Gy), -36.2±17.6% (-2.3Gy), and -36.4 ± 17.4% (-2.3Gy) were found. The differences in IR-CTV (D90) were -38.8 ± 15.4% (-2.4Gy), -42.3 ± 14.5% (-2.6Gy), and -41.7 ± 15.4%(-2.5Gy). The percent differences in the ICRU defined rectal and bladder points were found less than 1.5 ± 3.4% for the plans of POINT A and A-UI when normalized to the values of POINT H plan. On MRI-guided plans, the differences in HR-CTV (D90) were on average -10.8 ± 36.2% (-1.1Gy), -9.6 ± 39.0% (-1.2Gy), and -13.3 ± 38.1% (-1.5Gy) for POINT H, A, and A-UI, showing minimal changes from POINT definitions. The doses of different POINT were higher than HR-CTV (D90) for all sizes of HR-CTV. The correlation between HR-CTV coverage and Point A doses, in both conventional and MRI-guided plans were significantly affected by HR-CTV volume but minimally by the definitions of Point A.